Compare DXC & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DXC | STOK |
|---|---|---|
| Founded | 1959 | 2014 |
| Country | United States | United States |
| Employees | 130000 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2016 | 2019 |
| Metric | DXC | STOK |
|---|---|---|
| Price | $11.97 | $33.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $15.33 | ★ $39.20 |
| AVG Volume (30 Days) | ★ 2.1M | 653.6K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 356.52 | 92.73 |
| EPS | ★ 0.88 | N/A |
| Revenue | ★ $12,871,000,000.00 | $184,420,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $82.05 |
| P/E Ratio | $13.28 | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $11.54 | $5.35 |
| 52 Week High | $17.68 | $40.22 |
| Indicator | DXC | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 43.54 | 49.19 |
| Support Level | $11.72 | $31.60 |
| Resistance Level | $15.58 | $35.75 |
| Average True Range (ATR) | 0.40 | 2.33 |
| MACD | 0.05 | -0.40 |
| Stochastic Oscillator | 24.09 | 36.38 |
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.